FDA Enforcement In Brief
This article was originally published in The Tan Sheet
Executive Summary
Perrigo facility undergoes reinspection
You may also be interested in...
Perrigo Takes Two Steps Forward: Generic Allegra Launch, Manufacturing Compliance
Perrigo stokes momentum behind already healthy sales growth with significant steps in separate areas: a green light for regulatory compliance at its main manufacturing plant, and the launch of its generic OTC versions of Sanofi-Aventis' Allegra.
Perrigo Absorbs Plant Remediation Sales Hit, But PBM Progresses In Q1
Continuing remediation at a facility that received an FDA warning letter took a bite out of first-quarter sales for Perrigo, but the private labeler sees continued upside in branded competitor recalls and infant formula growth in the rest of fiscal 2011.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.